Home
RDHL
RDHL News

Latest Redhill Biopharma Ltd. (RDHL) News on September 13, 2025

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

PR Newswire

8 days ago

RedHill Biopharma Announces First Half 2025 Financial Results and Operational Highlights

MT Newswires

2 months ago

Sector Update: Health Care Stocks Softer Monday Afternoon

MT Newswires

2 months ago

RedHill Biopharma Receives Positive Feedback From FDA on Crohn's Disease Treatment; Shares Rise

Ares and Ansley Park Capital provide asset-based and equipment financing to Shimmick

Leasing Life

3 months ago

Ares and Ansley Park Capital provide asset-based and equipment financing to Shimmick

BP, EOG achieve first gas from Mento field, offshore Trinidad

Offshore Technology

3 months ago

BP, EOG achieve first gas from Mento field, offshore Trinidad

Macron urges Asia, Europe to unite to resist 'spheres of coercion'

AFP

3 months ago

Macron urges Asia, Europe to unite to resist 'spheres of coercion'

Name Game: Shoe Carnival Is Converting More Stores to Shoe Station Banner

Footwear News

3 months ago

Name Game: Shoe Carnival Is Converting More Stores to Shoe Station Banner

Business Wire

3 months ago

Form 8.3 - American Axle & Manufacturing Holdings, Inc.

Ulta Stock Jumps as Beauty Product Spending Continues

Investopedia

3 months ago

Ulta Stock Jumps as Beauty Product Spending Continues

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

GlobeNewswire

3 months ago

Silicon Photonics Market Set to Surge to USD 13.9 Billion by 2034, Driven by 12.5% CAGR | Exactitude Consultancy

Anti-money Laundering (AML) Market worth $9.38 billion by 2030- Exclusive Report by MarketsandMarkets™

PR Newswire

3 months ago

Anti-money Laundering (AML) Market worth $9.38 billion by 2030- Exclusive Report by MarketsandMarkets™

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

PR Newswire

4 months ago

RedHill Biopharma Secures Kukbo Asset Freeze Following RedHill's $8.25 Million Plus Legal Fees New York Supreme Court Summary Judgment Win

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

PR Newswire

4 months ago

RedHill-Supported Medscape H. Pylori Educational Program to Launch at Major Gastroenterology Congress

MT Newswires

5 months ago

RedHill Biopharma Obtains Allowance for Chinese Patent Application for COVID-19 Treatment

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

PR Newswire

5 months ago

RedHill Biopharma Secures Allowance of Key Chinese Patent Application for Proprietary COVID-19 Treatment, RHB-107

MT Newswires

5 months ago

RedHill Biopharma Gets Nasdaq Noncompliance Notice

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

PR Newswire

5 months ago

RedHill Biopharma Receives Nasdaq Notification Regarding Minimum Stockholders' Equity Deficiency

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

PR Newswire

5 months ago

RedHill Biopharma's Positive Opaganib Weight Loss & Diabetes Data Published: Signals Potential $100B Market Disruption

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

PR Newswire

5 months ago

RedHill Biopharma Announces Full-Year 2024 Financial Results and Operational Highlights

MT Newswires

6 months ago

RedHill Biopharma Plans to File for UK Approval of H.Pylori Treatment

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

PR Newswire

6 months ago

RedHill Biopharma to Submit FDA-Approved Talicia® for UK Marketing Authorisation

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

PR Newswire

6 months ago

RedHill Biopharma Advances its Groundbreaking Late-Stage Crohn's Disease Program Building on Statistically Significant Positive RHB-104 Phase 3 Results

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

PR Newswire

7 months ago

RedHill Presents Business Update at the Sachs' European Life Sciences CEO Forum

RedHill and Hyloris sign agreement for Bekinda’s development

Pharmaceutical Technology

7 months ago

RedHill and Hyloris sign agreement for Bekinda’s development

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

PR Newswire

7 months ago

RedHill Licenses RHB-102 for Commercialization Worldwide Excluding North America to Hyloris for up to $60 Million in Potential Milestone Payments Plus Royalties

RedHill Biopharma launches trial of combination therapy for prostate cancer

Clinical Trials Arena

7 months ago

RedHill Biopharma launches trial of combination therapy for prostate cancer

MT Newswires

7 months ago

RedHill Biopharma Begins Phase 2 Study of Opaganib, Darolutamide for Advanced Prostate Cancer; Shares Rise

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

PR Newswire

7 months ago

RedHill Announces Initiation of Phase 2 Study of Opaganib and Darolutamide in Advanced Prostate Cancer

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

PR Newswire

8 months ago

RedHill's Talicia® Adds 8 Million Lives With Coverage by Humana®'s Part D Plan. Also, New Data Supporting Simplified Three-Times Daily Talicia Dosing Published

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

PR Newswire

9 months ago

Radioprotective Activity of RedHill's Opaganib for GI-ARS Confirmed in New RNCP/NIAID Study - Discussions Ongoing with U.S. Government on Advanced Development

RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court

TipRanks

9 months ago

RedHill Biopharma awarded judgement of approx $8M by NY Supreme Court

MT Newswires

9 months ago

RedHill Biopharma Awarded $8 Million in Legal Case Against Kukbo

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

PR Newswire

9 months ago

RedHill Biopharma Awarded Judgment of Approximately $8 Million Plus Costs by New York Supreme Court

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

PR Newswire

a year ago

RedHill Selected to Present Opaganib at Conference Organized by U.S. Government's JPEO-CBRND

RedHill Biopharma and Duke Collaborate on Opaganib Development

TipRanks

a year ago

RedHill Biopharma and Duke Collaborate on Opaganib Development

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

PR Newswire

a year ago

RedHill Announces Collaboration with a Leading U.S. Academic Medical Center to Develop Opaganib as a Countermeasure Against Phosgene Inhalation Injury

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

PR Newswire

a year ago

RedHill Biopharma Secures U.S. Government Funding through BARDA to Advance Opaganib for Ebola Treatment

RedHill Biopharma Secures Opaganib COVID-19 Patent

TipRanks

a year ago

RedHill Biopharma Secures Opaganib COVID-19 Patent

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

PR Newswire

a year ago

RedHill and Medi-Cal Deal Maintains Talicia® Reimbursement Without Prior Authorization for 15 Million Californians

MT Newswires

a year ago

RedHill Biopharma Says US Issues New Coronavirus Patent for Opaganib

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

PR Newswire

a year ago

RedHill Announces New U.S. Coronavirus Patent for Opaganib, Valid Through 2041

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

PR Newswire

a year ago

RedHill's Talicia® Listed as First-Line Choice for H. pylori in New American College of Gastroenterology Guidelines

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire

a year ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

PR Newswire

a year ago

New Peer-Reviewed Publication of Opaganib Phase 2/3 Data Shows 62% Reduction in COVID-19 Mortality

RedHill Biopharma Announces First Half 2024 Business Highlights

PR Newswire

a year ago

RedHill Biopharma Announces First Half 2024 Business Highlights

MT Newswires

a year ago

RedHill Biopharma Says Opaganib Gets FDA Orphan Drug Designation for Neuroblastoma

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

PR Newswire

a year ago

RedHill's Opaganib Granted Orphan Drug Designation by the FDA for Childhood Cancer, Neuroblastoma

Three Undiscovered Gems in the United States Market

Simply Wall St.

a year ago

Three Undiscovered Gems in the United States Market

Talicia® Launched in the United Arab Emirates

PR Newswire

a year ago

Talicia® Launched in the United Arab Emirates

Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested

TipRanks

a year ago

Upcoming Stock Splits This Week (August 19 to August 23) – Stay Invested

MT Newswires

a year ago

Redhill Biopharma's Shares Jump Premarket on Positive Study Results for Opaganib

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

PR Newswire

a year ago

RedHill Announces Positive Obesity and Diabetes Results with Opaganib

MT Newswires

a year ago

Redhill Biopharma to Change American Depositary Share Ratio

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

PR Newswire

a year ago

RedHill Biopharma Announces Plan to Implement ADS Ratio Change

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

PR Newswire

a year ago

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

PR Newswire

a year ago

RedHill Biopharma Strengthens Cash Balance, Settles Obligations and Removes Talicia® Lien

RedHill Biopharma Terminates License Agreement for Aemcolo®

PR Newswire

a year ago

RedHill Biopharma Terminates License Agreement for Aemcolo®

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

PR Newswire

a year ago

RedHill Announces a New Patent Covering Opaganib in Combination with Immune Checkpoint Inhibitors, Valid Through 2040

MT Newswires

a year ago

Redhill Biopharma Awarded China Patent for Investigational Ebola Drug Opaganib

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

PR Newswire

a year ago

RedHill Announces New Opaganib Chinese Patent Against Ebola Virus Valid Through 2035

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

PR Newswire

a year ago

RedHill Announces First Patient Enrolled in U.S. Government-Supported COVID-19 Study

RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)

Simply Wall St.

a year ago

RedHill Biopharma Full Year 2023 Earnings: EPS: US$4.00 (vs US$46.29 loss in FY 2022)

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

PR Newswire

a year ago

RedHill Biopharma Announces Full-Year 2023 Results and Operational Highlights

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

PR Newswire

a year ago

RedHill Biopharma Announces $1.25 Million Registered Direct Offering at a Premium to Market Price

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

PR Newswire

2 years ago

RedHill Announces New USPTO Patent Covering Talicia® Through 2034

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

PR Newswire

2 years ago

RedHill's Opaganib Selected for Evaluation by BARDA and NIH Countermeasures Programs

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

PR Newswire

2 years ago

RedHill's Opaganib Protects Against Radiation-Induced Lung Inflammation and Fibrosis - New Publication

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

PR Newswire

2 years ago

RedHill Biopharma Announces Closing of $8 Million Registered Direct Offering

RedHill Biopharma Announces $8 Million Registered Direct Offering

PR Newswire

2 years ago

RedHill Biopharma Announces $8 Million Registered Direct Offering

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

GlobeNewswire

2 years ago

CENTOGENE and the Laboratory of Human Genetics of Infectious Diseases at Institut Imagine Announce Rare Disease Research Collaboration

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

PR Newswire

2 years ago

RedHill Announces New USPTO Patent Grant for Talicia® for H. pylori Treatment Through 2042

11 Hyper-Growth Stocks Billionaires Are Loading Up On

Insider Monkey

2 years ago

11 Hyper-Growth Stocks Billionaires Are Loading Up On

Mullen Automotive Regains Compliance with Nasdaq Minimum Bid Price Requirement

GlobeNewswire

2 years ago

Mullen Automotive Regains Compliance with Nasdaq Minimum Bid Price Requirement

Indonesia Energy to Present at The Microcap Conference in Atlantic City on January 31 and again on February 1, 2024

GlobeNewswire

2 years ago

Indonesia Energy to Present at The Microcap Conference in Atlantic City on January 31 and again on February 1, 2024

Spero Therapeutics, Inc. (NASDAQ:SPRO): Are Analysts Optimistic?

Simply Wall St.

2 years ago

Spero Therapeutics, Inc. (NASDAQ:SPRO): Are Analysts Optimistic?

Vuzix to Showcase the Broad Functionality AI Brings to its Industry Leading AR Smart Glasses at CES 2024

PR Newswire

2 years ago

Vuzix to Showcase the Broad Functionality AI Brings to its Industry Leading AR Smart Glasses at CES 2024

Gorilla Technology Group’s AI Solution Assists London’s Metropolitan Police Secure Successful Convictions in Complex Homicide Investigation

GlobeNewswire

2 years ago

Gorilla Technology Group’s AI Solution Assists London’s Metropolitan Police Secure Successful Convictions in Complex Homicide Investigation

BayFirst Financial Corp. Announces Fourth Quarter 2023 Conference Call and Webcast

GlobeNewswire

2 years ago

BayFirst Financial Corp. Announces Fourth Quarter 2023 Conference Call and Webcast

Could The Market Be Wrong About GEN Restaurant Group, Inc. (NASDAQ:GENK) Given Its Attractive Financial Prospects?

Simply Wall St.

2 years ago

Could The Market Be Wrong About GEN Restaurant Group, Inc. (NASDAQ:GENK) Given Its Attractive Financial Prospects?

11 High Growth Micro-Cap Stocks to Buy

Insider Monkey

2 years ago

11 High Growth Micro-Cap Stocks to Buy

Workhorse Highlights Achievements in 2023 Year-End Letter to Shareholders

GlobeNewswire

2 years ago

Workhorse Highlights Achievements in 2023 Year-End Letter to Shareholders

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

PR Newswire

2 years ago

RedHill and U.S. Army Announce Opaganib and RHB-107 Combinations with Remdesivir Show Distinct Synergistic Effect Against Ebola

Investors in Vuzix (NASDAQ:VUZI) from three years ago are still down 74%, even after 11% gain this past week

Simply Wall St.

2 years ago

Investors in Vuzix (NASDAQ:VUZI) from three years ago are still down 74%, even after 11% gain this past week

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

GlobeNewswire

2 years ago

CytoSorbents Announces Closing of $10.3 Million Registered Direct Offering

PR Newswire

2 years ago

Neonode Launches Sharpened Strategy with Full Focus on Its Licensing Business

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

PR Newswire

2 years ago

RedHill Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement

Neonode Awarded by Leading Commercial Vehicle OEM to Supply MultiSensing® Driver Monitoring System Software

PR Newswire

2 years ago

Neonode Awarded by Leading Commercial Vehicle OEM to Supply MultiSensing® Driver Monitoring System Software

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

PR Newswire

2 years ago

RedHill Announces New, Non-Dilutive External Funding of Entire RHB-107 COVID-19 300-Patient Phase 2 Study

Fathom Holdings Prices Underwritten Public Offering of Common Stock

PR Newswire

2 years ago

Fathom Holdings Prices Underwritten Public Offering of Common Stock

American Robotics CEO, Timothy Tenne to Lead Panel Discussion on Drone Law at Upcoming Administrative Law Conference Sponsored by the American Bar Association

ACCESSWIRE

2 years ago

American Robotics CEO, Timothy Tenne to Lead Panel Discussion on Drone Law at Upcoming Administrative Law Conference Sponsored by the American Bar Association

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

PR Newswire

2 years ago

RedHill Biopharma Announces FDA Grant of 5-Year U.S. Market Exclusivity for Talicia® with IP Protection Running to 2034

Business Wire

2 years ago

Deswell Announces First Half 2024 Results

Polar Asset Management Partners Inc. Adjusts Stake in GEN Restaurant Group Inc.

GuruFocus.com

2 years ago

Polar Asset Management Partners Inc. Adjusts Stake in GEN Restaurant Group Inc.

Middlefield (MBCN) Stock Gains on Special Dividend Announcement

Zacks

2 years ago

Middlefield (MBCN) Stock Gains on Special Dividend Announcement

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

PR Newswire

2 years ago

RedHill Biopharma Announces the Transfer of its Listing to The Nasdaq Capital Market

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

GlobeNewswire

2 years ago

Achilles Therapeutics Reports Third Quarter 2023 Financial Results and Recent Highlights

Even With A 27% Surge, Cautious Investors Are Not Rewarding Nutex Health Inc.'s (NASDAQ:NUTX) Performance Completely

Simply Wall St.

2 years ago

Even With A 27% Surge, Cautious Investors Are Not Rewarding Nutex Health Inc.'s (NASDAQ:NUTX) Performance Completely

Associated Press Finance

2 years ago

Almaden Minerals: Q3 Earnings Snapshot

PR Newswire

2 years ago

NUTEX HEALTH REPORTS THIRD QUARTER 2023 FINANCIAL RESULTS

Aterian Inc (ATER) Reports Q3 2023 Earnings: Net Loss Narrows Significantly

GuruFocus.com

2 years ago

Aterian Inc (ATER) Reports Q3 2023 Earnings: Net Loss Narrows Significantly

Share on Social Networks: